Gyre Therapeutics GYRE
NASDAQ GYRE
$6.77 +0.33 (+5.12%)
As of: Sep 4, 2026 · 3:09 PM EDT

Gyre Therapeutics (GYRE) Non Operating Interest Expenses (2010 - 2024)

Analysis

Gyre Therapeutics (GYRE) Non Operating Interest Expenses (2010 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Gyre Therapeutics 683.33 Mn 625.93 Mn 26.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 315,000.00
Mar 31, 2023 643,000.00
Dec 31, 2020 71,000.00
Sep 30, 2020 7,000.00
Dec 31, 2019 -34,000.00
Dec 31, 2015 22,000.00
Sep 30, 2015 1.44 Mn
Jun 30, 2015 39,000.00
Dec 31, 2014 3,000.00
Sep 30, 2014 5,000.00
Jun 30, 2014 6,000.00
Mar 31, 2014 9,000.00
Dec 31, 2013 10,000.00
Sep 30, 2013 13,000.00
Jun 30, 2013 14,000.00
Mar 31, 2013 16,000.00
Dec 31, 2012 18,000.00
Sep 30, 2012 20,000.00
Jun 30, 2012 22,000.00
Mar 31, 2012 26,000.00